ClinicalTrials.gg

Program

balcinrenone

Also written as “AZD9977”, “Balcinrenone/dapagliflozin” and “balcinrenone/ dapagliflozin”.

Its studies are mostly in Heart Failure · Renal Insufficiency · Renal Insufficiency, Chronic · Fasting · Cardiovascular Diseases, led by AstraZeneca.

Furthest: phase 3, since May 29, 202615 company-led studies, 1 open or runningNext primary completion: Jul 1, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca151 open or runningphase 3since May 29, 2026Jun 18, 2015Jul 1, 2030phase 3 · NCT07624305
  • Named in AstraZeneca’s own pipeline as balcinrenone/dapagliflozin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: fortrea, parexel and quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jun 18, 2015.

  1. Aug 24, 2015Phase 1 study in PharmacodynamicsNCT02532998 · 40 enrolled · United Kingdom
  2. Sep 24, 2015Phase 1 study in PharmacokineticsNCT02560363 · United Kingdom
  3. Jan 25, 2018Phase 1 study in Heart FailureNCT03435276 · 27 enrolled · United Kingdom
  4. Feb 15, 2018Phase 1 study in Heart FailureNCT03450759 · 13 enrolled · United Kingdom
  5. Sep 21, 2018Phase 1 study in Heart FailureNCT03682497 · 68 enrolled · Bulgaria, Czechia, Poland and more
  6. Dec 12, 2018Phase 1 study in Heart FailureNCT03801967 · 28 enrolled · United Kingdom
  7. Feb 14, 2019Phase 1 study in Heart FailureNCT03843060 · 14 enrolled · United States
  8. Jun 19, 2020Phase 1 study in Renal InsufficiencyNCT04469907 · 18 enrolled · United States
  9. Dec 17, 2020Phase 1 study in Cardiovascular DiseasesNCT04686591 · 8 enrolled · United Kingdom
  10. Apr 16, 2024Phase 1 study in Hepatic ImpairmentNCT06388616 · 30 enrolled · United States
  11. Sep 25, 2024Phase 1 study in Healthy VolunteerNCT06651021 · 10 enrolled · China
  12. May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT06979388 · 14 enrolled · United Kingdom
  13. May 29, 2026Phase 3 study in Renal Insufficiency, ChronicPhase 3 reachedNCT07624305 · 2,800 planned · United States, Argentina, Austria and more
  14. Jul 13, 2026Phase 1 study in Renal InsufficiencyNCT07754331 · 10 enrolled · United States

Ahead

  1. Jul 1, 2030Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07624305

TargetBeta

NR3C2 →read by rule
“Mineralocorticoid receptor modulator”ChEMBL 37, by rule

Other programs on NR3C2

ProgramCompanyFurthest phaseStudies
finerenoneruleBayerphase 425
drospirenoneruleestetraphase 420
vamorolonerulereveragen-biopharma-incphase 411
Spironolactonerulecmp-development-llcphase 48
HRS-1780Jiangsu HengRui Medicinephase 37

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07754331Renal Insufficiency · United States1CompletedOct 6, 202610
NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more3RecruitingJul 1, 20302,800
NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom1CompletedJul 12, 202514
NCT06651021Healthy Volunteer · China1CompletedOct 28, 202410
NCT06388616Hepatic Impairment · United States1CompletedSep 5, 202430
NCT04686591Cardiovascular Diseases · United Kingdom1CompletedFeb 4, 20218
NCT04469907Renal Insufficiency · United States1CompletedOct 28, 202118
NCT03843060Heart Failure · United States1CompletedApr 1, 201914
NCT03801967Heart Failure · United Kingdom1CompletedMay 2, 201928
NCT03682497Heart Failure · Bulgaria, Czechia, Poland and more1TerminatedMar 31, 202068
NCT03450759Heart Failure · United Kingdom1CompletedJun 6, 201813
NCT03435276Heart Failure · United Kingdom1CompletedJun 13, 201827
NCT02560363Pharmacokinetics · United Kingdom1WithdrawnJan 20160
NCT02532998Pharmacodynamics · United Kingdom1CompletedDec 201540
NCT02484729Safety · United Kingdom1CompletedNov 2015196

How it is read

Names in the registry

  • “AZD9977”, 5 entries
  • “Balcinrenone/dapagliflozin”, 2 entries
  • “balcinrenone/ dapagliflozin”, 1 entry
  • “balcinrenone/dapagliflozin”, 1 entry
  • “Balcinrenone”, 1 entry

Codes read as this program: AZD9977.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.